Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CHEK Stock Forecast 2025-2026
$1.98
Current Price
$11.56M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CHEK Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CHEK Price Momentum
+19.3%
1 Week Change
+4.2%
1 Month Change
+157.1%
1 Year Change
+100.0%
Year-to-Date Change
-36.9%
From 52W High of $3.13
+252.7%
From 52W Low of $0.56
📊 TOP ANALYST CALLS
Did CHEK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Check Cap is one of their latest high-conviction picks.
Latest CHEK Stock Price Targets & Analyst Predictions
CHEK has shown a year-to-date change of 100.0% and a 1-year change of 157.1%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CHEK. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHEK Analyst Ratings
3
Buy
0
Hold
0
Sell
CHEK Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.98
Latest CHEK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHEK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 7, 2023 | HC Wainwright & Co. | Yi Chen | Neutral | Downgrade | $N/A |
| May 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $7.00 |
| Apr 5, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $7.00 |
| Aug 9, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $3.00 |
| Mar 17, 2021 | Dawson James | Neutral | Downgrade | $N/A | |
| Mar 16, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $4.00 |
| Nov 19, 2020 | HC Wainwright & Co. | Buy | Maintains | $1.50 | |
| Apr 24, 2020 | HC Wainwright & Co. | Buy | Reiterates | $2.00 | |
| Apr 24, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Feb 5, 2019 | Dougherty | Buy | Initiates | $N/A | |
| Feb 5, 2019 | Dougherty & Co. | Buy | Initiates | $N/A | |
| May 23, 2018 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $14.00 |
| May 23, 2018 | H.C. Wainwright | Buy | Maintains | $N/A | |
| Mar 16, 2016 | Chardan Capital | Buy | Maintains | $6.00 | |
| Oct 8, 2015 | Maxim Group | Buy | Initiates | $N/A |
Check-Cap Ltd. (CHEK) Competitors
The following stocks are similar to Check Cap based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Check-Cap Ltd. (CHEK) Financial Data
Check-Cap Ltd. has a market capitalization of $11.56M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -226.2%.
Valuation Metrics
Market Cap
$11.56M
Enterprise Value
$9.76M
P/E Ratio
-0.5x
PEG Ratio
-0.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+2.3%
Current Ratio
0.1x
Debt/Equity
-0.1x
ROE
-226.2%
ROA
-46.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Check-Cap Ltd. (CHEK) Business Model
About Check-Cap Ltd.
What They Do
Develops innovative colorectal cancer screening solutions.
Business Model
The company generates revenue through its advanced capsule-based screening platform that offers a non-invasive and radiation-free alternative to traditional colorectal cancer screening methods. By improving patient compliance and increasing screening participation rates, Check-Cap aims to establish partnerships with healthcare providers and organizations, thereby expanding its market reach and enhancing its financial performance.
Additional Information
Check-Cap's technology is designed to improve early detection of colorectal cancer, which can lead to better patient outcomes and lower healthcare costs. The company's focus on patient-friendly solutions positions it as a key player in the preventive care segment, appealing to both healthcare providers and regulators in the effort to enhance diagnostic efficiency.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
85
CEO
Mr. David Lontini
Country
Israel
IPO Year
2015
Website
www.check-cap.comCheck-Cap Ltd. (CHEK) Latest News & Analysis
Latest News
Quick Summary
MBody AI ($CHEK) is expanding its hardware-agnostic MBody AI Orchestrator(TM) platform globally, enhancing its presence in the embodied AI market.
Why It Matters
MBody AI's global expansion of its platform enhances market presence, potentially driving revenue growth and investor confidence in the company's future performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Check-Cap Ltd. offers shareholders exclusive early access to a leading embodied AI company, focusing on global growth and long-term value creation.
Why It Matters
Early access to a leading embodied AI company suggests potential for substantial returns, innovation advancements, and long-term value, indicating a favorable investment opportunity.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
MediPharm Labs' management has not held a conference call since Q2 2024, following a 99% stock value decline costing shareholders $1 billion. Apollo Capital plans to nominate new directors for change.
Why It Matters
MediPharm's management's avoidance of shareholder communication raises concerns about accountability and transparency, potentially impacting investor confidence and stock performance amid leadership changes.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
MediPharm Labs Corp. (TSX: LABS) has filed its Management Information Circular and proxy materials for its Annual and Special Meeting of Shareholders on June 16, 2025, available on SEDAR+.
Why It Matters
MediPharm Labs' filing for its Annual and Special Meeting signals upcoming shareholder decisions, potentially impacting corporate strategy, governance, and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Apollo Technology Capital is urging MediPharm Labs shareholders to vote for a board overhaul at the June 10, 2025 meeting, citing a 99% stock decline and management failures.
Why It Matters
MediPharm's stock plummeting over 99% signals severe mismanagement. Apollo's push for board changes highlights potential for improved governance, impacting future shareholder value significantly.
Source: PRNewsWire
Market Sentiment:
Neutral
Why Is Check-Cap (CHEK) Stock Up 44% Today?
1 year ago
Quick Summary
Check-Cap (NASDAQ: CHEK) shares are rising following its announcement of a business combination with Nobul AI, transferring leadership to Nobul AI's team and shareholders.
Why It Matters
The rise in Check-Cap's stock reflects investor optimism about the business combination with Nobul AI, suggesting potential growth and new strategic direction under fresh leadership.
Source: InvestorPlace
Market Sentiment:
Positive
Frequently Asked Questions About CHEK Stock
What is Check-Cap Ltd.'s (CHEK) stock forecast for 2026?
Analyst forecasts for Check-Cap Ltd. (CHEK) are not currently available. The stock is trading at $1.98.
Is CHEK stock a good investment in 2026?
According to current analyst ratings, CHEK has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHEK stock?
Price predictions from Wall Street analysts for CHEK are not currently available. The stock is trading at $1.98.
What is Check-Cap Ltd.'s business model?
The company generates revenue through its advanced capsule-based screening platform that offers a non-invasive and radiation-free alternative to traditional colorectal cancer screening methods. By improving patient compliance and increasing screening participation rates, Check-Cap aims to establish partnerships with healthcare providers and organizations, thereby expanding its market reach and enhancing its financial performance.
What is the highest forecasted price for CHEK Check-Cap Ltd.?
Price targets from Wall Street analysts for CHEK are not currently available. The stock is trading at $1.98.
What is the lowest forecasted price for CHEK Check-Cap Ltd.?
Price targets from Wall Street analysts for CHEK are not currently available. The stock is trading at $1.98.
What is the overall CHEK consensus from analysts for Check-Cap Ltd.?
The overall analyst consensus for CHEK is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are CHEK stock price projections?
Stock price projections, including those for Check-Cap Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 9:30 AM UTC